EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections

Sujata M Bhavnani iD, Jeffrey P Hammel, Elizabeth A Lakota, Kathryn Liolios, Michael Trang iD, Christopher M Rubino iD, Judith N Steenbergen, Lawrence Friedrich, Evan Tzanis, Paul G Ambrose iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01281-23 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Sujata M Bhavnani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Tetracyclines, Microbial Sensitivity Tests. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacokinetic-pharmacodynamic (PK-PD) relationships for efficacy were evaluated using data from omadacycline-treated patients with acute bacterial skin and skin structure infections (ABSSSI) enrolled in two phase 3 studies. Patients received omadacycline 100 mg intravenously (IV) every 12 hours for two doses, followed by 100 mg IV every 24 hours (q24h), with the option to switch to 300 mg oral (PO) q24h after 3 days or 450 mg PO q24h for two doses, followed by 300 mg PO q24h for a total duration of 7–14 days. Clinical response was evaluated at 48–72 hours [early clinical response (ECR)], end of treatment (EOT), and 7–14 days after EOT. Using a population pharmacokinetic (PK) model and PK data from patients with Staphylococcus aureus at baseline, omadacycline free-drug plasma area under the concentration-time curve (AUC) values were determined, and the relationships between free-drug plasma AUC:MIC ratio and dichotomous efficacy endpoints were evaluated. Using these relationships, the population PK model, simulation, and an omadacycline MIC distribution for S. aureus , mean percent probabilities of response were evaluated. Statistically significant PK-­PD relationships were identified for ECR ( P = 0.016 and 0.013 for optimized two- and three-group free-drug plasma AUC:MIC ratios, respectively). At an MIC value of 0.5 µg/mL, percent probabilities of model-predicted success for ECR based on the univariable PK-PD relationships using continuous and two-group free-drug plasma AUC:MIC ratio variables were 91.9 and 95.6%, respectively, for the IV-to-PO dosing regimen and 89.3 and 88.4%, respectively, for the PO-only dosing regimen. These data support for omadacycline IV-to-PO and PO-only dosing regimens for ABSSSI and an omadacycline susceptibility breakpoint of 0.5 µg/mL for S. aureus .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsTetracyclinesMicrobial Sensitivity TestsHumansMaleFemaleMiddle AgedAdultArea Under CurveStaphylococcus aureusSkin Diseases, BacterialAgedStaphylococcal Skin InfectionsAdministration, OralDrug Administration Schedule

Stichwörter der Autor:innen

acute bacterial skin and skin structure infectionsomadacyclinepharmacokinetics-pharmacodynamics

Substanzen

omadacyclineAnti-Bacterial AgentsTetracyclines

Autor:innen und Institutionen

  • Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
  • Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.

ORCID-Profile: Sujata M Bhavnani, Michael Trang, Christopher M Rubino, Paul G Ambrose

Zitieren

APA

Bhavnani, S. M., Hammel, J. P., Lakota, E. A., Liolios, K., Trang, M., Rubino, C. M., Steenbergen, J. N., Friedrich, L., Tzanis, E., & Ambrose, P. G. (2024). Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01281-23

Vancouver

Bhavnani SM, Hammel JP, Lakota EA, Liolios K, Trang M, Rubino CM, et al. Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01281-23

BibTeX
@article{Bhavnani2024,
  author = {Bhavnani, Sujata M and Hammel, Jeffrey P and Lakota, Elizabeth A and Liolios, Kathryn and Trang, Michael and Rubino, Christopher M and Steenbergen, Judith N and Friedrich, Lawrence and Tzanis, Evan and Ambrose, Paul G},
  title = {Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01281-23}
}
Kostenlos starten →